TG Therapeutics, Inc. (TGTX)
TGTX Stock Price Chart
Explore TG Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze TGTX price movements and trends.
TGTX Company Profile
Discover essential business fundamentals and corporate details for TG Therapeutics, Inc. (TGTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 May 2010
Employees
352.00
Website
https://www.tgtherapeutics.comCEO
Michael S. Weiss
Description
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
TGTX Financial Timeline
Browse a chronological timeline of TG Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 3 Aug 2026
EPS estimate is $0.32, while revenue estimate is $228.97m.
Earnings released on 6 May 2026
EPS came in at $0.14 falling short of the estimated $0.23 by -39.13%, while revenue for the quarter reached $204.92m , beating expectations by +2.29%.
Earnings released on 26 Feb 2026
EPS came in at $0.14 falling short of the estimated $0.35 by -60.00%, while revenue for the quarter reached $192.57m , beating expectations by +0.41%.
Earnings released on 3 Nov 2025
EPS came in at $2.43 surpassing the estimated $0.24 by +912.50%, while revenue for the quarter reached $161.71m , missing expectations by -16.56%.
Earnings released on 4 Aug 2025
EPS came in at $0.17 falling short of the estimated $0.32 by -46.88%, while revenue for the quarter reached $141.15m , missing expectations by -3.50%.
Earnings released on 5 May 2025
EPS came in at $0.03 falling short of the estimated $0.18 by -83.33%, while revenue for the quarter reached $120.86m , missing expectations by -9.94%.
Earnings released on 3 Mar 2025
EPS came in at $0.15 surpassing the estimated $0.08 by +87.50%, while revenue for the quarter reached $108.19m , missing expectations by -0.57%.
Earnings released on 4 Nov 2024
EPS came in at $0.02 falling short of the estimated $0.03 by -33.33%, while revenue for the quarter reached $83.88m , missing expectations by -15.09%.
Earnings released on 6 Aug 2024
EPS came in at $0.04 surpassing the estimated -$0.05 by +180.00%, while revenue for the quarter reached $73.47m , beating expectations by +11.50%.
Earnings released on 1 May 2024
EPS came in at -$0.07 falling short of the estimated -$0.04 by -96.02%, while revenue for the quarter reached $63.47m , beating expectations by +16.23%.
Earnings released on 28 Feb 2024
EPS came in at -$0.09 surpassing the estimated -$0.12 by +25.00%, while revenue for the quarter reached $43.97m , beating expectations by +9.76%.
Earnings released on 1 Nov 2023
EPS came in at $0.73 surpassing the estimated $0.12 by +508.33%, while revenue for the quarter reached $165.82m , beating expectations by +328.68%.
Earnings released on 1 Aug 2023
EPS came in at -$0.34 falling short of the estimated -$0.26 by -30.77%, while revenue for the quarter reached $16.07m , missing expectations by -65.90%.
Earnings released on 1 May 2023
EPS came in at -$0.28 surpassing the estimated -$0.36 by +22.22%, while revenue for the quarter reached $7.80m , missing expectations by -45.93%.
Earnings released on 28 Feb 2023
EPS came in at -$0.39 falling short of the estimated -$0.26 by -50.00%, while revenue for the quarter reached $80.00k , missing expectations by -95.01%.
Earnings released on 10 Nov 2022
EPS came in at -$0.26 surpassing the estimated -$0.33 by +21.21%, while revenue for the quarter reached $94.00k , missing expectations by -93.54%.
Earnings released on 8 Aug 2022
EPS came in at -$0.30 surpassing the estimated -$0.49 by +38.78%, while revenue for the quarter reached $594.00k , beating expectations by +238.60%.
Earnings released on 10 May 2022
EPS came in at -$0.51 surpassing the estimated -$0.55 by +7.27%, while revenue for the quarter reached $2.02m , missing expectations by -3.11%.
Earnings released on 1 Mar 2022
EPS came in at -$0.70 falling short of the estimated -$0.62 by -12.90%, while revenue for the quarter reached $2.32m , beating expectations by +3.62%.
Earnings released on 4 Nov 2021
EPS came in at -$0.65 falling short of the estimated -$0.56 by -16.07%, while revenue for the quarter reached $2.03m , missing expectations by -31.65%.
Earnings released on 2 Aug 2021
EPS came in at -$0.59 falling short of the estimated -$0.48 by -22.92%, while revenue for the quarter reached $1.55m , missing expectations by -55.73%.
TGTX Stock Performance
Access detailed TGTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
